MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood... (wishing to participate in thecall must R...)

HOME >> MEDICINE >> TECHNOLOGY

MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders

Date:12/13/2007

wishing to participate in the call must RSVP to conferencecalls@michaeljfox.org and will receive an e-mail reply with call-in details.

The overall selection of program awardees will be made exclusively by the Foundation under its standard peer-review process. Pre-proposals under this initiative are required and are due at 6 p.m. U.S. Eastern Time on Wednesday, February 13, 2008. Funding is anticipated in July 2008. Full information on how to apply is available on the Foundation's Web site, http://www.michaeljfox.org.

About The Michael J. Fox Foundation

The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease through an aggressively funded research agenda. To date, the Foundation has funded $100 million in research directly or through partnerships.

About Merck Serono

Merck Serono International S.A., the new division for innovative small molecules and biopharmaceuticals of Merck, was established following the acquisition of Serono and the integration of its business with the former Merck Ethicals Division. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, produces and commercializes innovative products to help patients with diseases with unmet needs. Our North American business operates in the United States and Canada under EMD Serono.

Merck Serono has leading brands serving patients with cancer (Erbitux (R)), multiple sclerosis (Rebif (R)), infertility (Gonal-f (R)), metabolic and cardiometabolic disorders (Glucophage (R), Concor (R), Saizen (R), Serostim (R)), as well as psoriasis (Raptiva (R)). With an annual R&D investment of EUR 1bn, we are committed to growing our business in specialist-focused therapeutic areas such as Neurodegenerative Diseases and Oncology, as well as new therapeutic areas potentially arising
'/>"/>

1

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
2. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
3. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
4. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
6. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
7. Test for Life Commends North Carolina Rules Commission for Implementing CDC Recommendations for HIV Testing
8. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
9. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
10. Molnlycke Drives Home the Fight Against Staph and Other MRSA Infections
11. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs

Post Your Comments:

MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood...(wishing to participate in thecall must R...),Health